Shares of Replimune Group Inc. (REPL) are down nearly 50% from their 52-week high of $17, recorded last November, and trade around $8.
This clinical-stage biotech company is developing innovative oncolytic immunotherapies using a proprietary HSV-1 strain and immune-activating transgenes to enhance T-cell stimulation and systemic immune response. Its lead investigational product is RP1, which is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP-R-) and a monomeric glycoprotein (GM-CSF) intended to maximize tumor-killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.
For comments and feedback: editorial@rttnews.com